AR088359A1 - FORMAS POLIMORFICAS DEL (1,1-DIOXO-l-4-TIOMORFOLINIL)-{6-[3-(4-FLUOROFENIL)-5-METIL-ISOXAZOL-4-ILMETOXI]-PIRIDIN-3-IL}-METANONA Y SU USO EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS - Google Patents
FORMAS POLIMORFICAS DEL (1,1-DIOXO-l-4-TIOMORFOLINIL)-{6-[3-(4-FLUOROFENIL)-5-METIL-ISOXAZOL-4-ILMETOXI]-PIRIDIN-3-IL}-METANONA Y SU USO EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOSInfo
- Publication number
- AR088359A1 AR088359A1 ARP120103860A ARP120103860A AR088359A1 AR 088359 A1 AR088359 A1 AR 088359A1 AR P120103860 A ARP120103860 A AR P120103860A AR P120103860 A ARP120103860 A AR P120103860A AR 088359 A1 AR088359 A1 AR 088359A1
- Authority
- AR
- Argentina
- Prior art keywords
- isoxazol
- dioxo
- methyl
- xrpd
- thiomorpholin
- Prior art date
Links
- -1 4-FLUOROPHENYL Chemical class 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 11
- 238000010586 diagram Methods 0.000 abstract 6
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 abstract 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- MGJURKDLIJVDEO-UHFFFAOYSA-N formaldehyde;hydrate Chemical compound O.O=C MGJURKDLIJVDEO-UHFFFAOYSA-N 0.000 abstract 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 abstract 1
- 230000009477 glass transition Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Formas sólidas del compuesto de la fórmula (1), así como a solvatos, complejos de inclusión con otros compuestos idóneos, a procesos de obtención, a composiciones farmacéuticas que contienen estas formas sólidas y a su utilización como medicamentos. Reivindicación 2: La (1,1-dioxo-1l⁶-tiomorfolin-4-il)-{6-[3-(4-fluoro-fenil)-5-metil-isoxazol-4-ilmetoxi]-piridin-3-il}-metanona monohidratada cristalina de la forma polimórfica B según la reivindicación 1, caracterizada por un diagrama de difracción XRPD que contiene picos XRPD en los ángulos de difracción 2-q de aproximadamente 13,3º, 20,6º, 22,5º. Reivindicación 6: La 1,1-dioxo-1l⁶-tiomorfolin-4-il)-{6-[3-(4-fluoro-fenil)-5-metil-isoxazol-4-ilmetoxi]-piridin-3-il}-metanona cristalina de la forma polimórfica anhidra C según la reivindicación 1, caracterizada por un diagrama de difracción XRPD que contiene picos XRPD en los ángulos de difracción 2-q de aproximadamente 17,4º, 23,4º. Reivindicación 10: La (1,1-dioxo-1l⁶-tiomorfolin-4-il)-{6-[3-(4-fluoro-fenil)-5-metil-isoxazol-4-ilmetoxi]-piridin-3-il}-metanona cristalina monosolvatada con trifluoroetanol de la forma polimórfica D según la reivindicación 1, caracterizada por un diagrama de difracción XRPD que contiene picos XRPD en los ángulos de difracción 2-q de aproximadamente 6,1º, 16,8º, 22,6º. Reivindicación 13: La (1,1-dioxo-1l⁶-tiomorfolin-4-il)-{6-[3-(4-fluoro-fenil)-5-metil-isoxazol-4-ilmetoxi]-piridin-3-il}-metanona cristalina de la forma polimórfica anhidra E según la reivindicación 1, caracterizada por un diagrama de difracción XRPD que contiene picos XRPD en los ángulos de difracción 2-q de aproximadamente 16,5º, 20,8º. Reivindicación 16: Un complejo de inclusión 1:1 de la (1,1-dioxo-1l⁶-tiomorfolin-4-il)-{6-[3-(4-fluoro-fenil)-5-metil-isoxazol-4-ilmetoxi]-piridin-3-il}-metanona con la g-ciclodextrina según la reivindicación 1. Reivindicación 17: El complejo de inclusión según la reivindicación 16, caracterizado por un diagrama de difracción XRPD que contiene picos XRPD en los ángulos de difracción 2-q de aproximadamente 7,4º, 14,9º, 16,7º, 21,8º. Reivindicación 22: La (1,1-dioxo-1l⁶-tiomorfolin-4-il)-{6-[3-(4-fluoro-fenil)-5-metil-isoxazol-4-ilmetoxil-piridin-3-il}-metanona amorfa, caracterizada por lo menos por un halo amorfo y la falta de un pico agudo de difracción de Bragg en el diagrama de difracción XRPD. Reivindicación 26: La forma amorfa según una cualquiera de las reivindicaciones de 22 a 25, caracterizada por una temperatura de transición vítrea Tg de 60ºC a 70ºC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11185993 | 2011-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088359A1 true AR088359A1 (es) | 2014-05-28 |
Family
ID=47019027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103860A AR088359A1 (es) | 2011-10-20 | 2012-10-17 | FORMAS POLIMORFICAS DEL (1,1-DIOXO-l-4-TIOMORFOLINIL)-{6-[3-(4-FLUOROFENIL)-5-METIL-ISOXAZOL-4-ILMETOXI]-PIRIDIN-3-IL}-METANONA Y SU USO EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8785435B2 (es) |
| EP (1) | EP2768821B1 (es) |
| JP (1) | JP5918856B2 (es) |
| KR (1) | KR20140079503A (es) |
| CN (1) | CN103889971B (es) |
| AR (1) | AR088359A1 (es) |
| AU (1) | AU2012318294B2 (es) |
| BR (1) | BR112014009288A8 (es) |
| CA (1) | CA2850441A1 (es) |
| DK (1) | DK2768821T3 (es) |
| ES (1) | ES2606547T3 (es) |
| HU (1) | HUE030298T2 (es) |
| IL (1) | IL231532A0 (es) |
| MX (1) | MX341492B (es) |
| PL (1) | PL2768821T3 (es) |
| RU (1) | RU2618524C2 (es) |
| SG (1) | SG11201401591WA (es) |
| SI (1) | SI2768821T1 (es) |
| WO (1) | WO2013057124A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| EA202090521A1 (ru) * | 2017-08-28 | 2020-06-10 | Юниверсити Оф Мэриленд, Балтимор | Новые модуляторы рецептора гамма-аминомасляной кислоты типа a против расстройств настроения |
| CR20200610A (es) | 2018-06-13 | 2021-02-05 | Hoffmann La Roche | Nuevos derivados de isoxazolit éter como pan de gaba a alfa 5 |
| MX2023004293A (es) | 2020-10-13 | 2023-05-03 | Boehringer Ingelheim Int | Proceso de reelaboracion. |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE352505C (de) | 1918-03-01 | 1922-04-27 | Metallbank | Verfahren zur Verarbeitung von Salmiakschlacken |
| DE3525205A1 (de) | 1984-09-11 | 1986-03-20 | Hoechst Ag, 6230 Frankfurt | Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols |
| GB9808663D0 (en) | 1998-04-23 | 1998-06-24 | Merck Sharp & Dohme | Therapeutic agents |
| JP2002522425A (ja) | 1998-08-07 | 2002-07-23 | カイロン コーポレイション | エストロゲンレセプターモジュレーターとしての置換イソオキサゾール |
| US6297256B1 (en) | 1999-06-15 | 2001-10-02 | Neurogen Corporation | Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| IT1314191B1 (it) | 1999-10-18 | 2002-12-06 | Recordati Chem Pharm | Derivati isossazolcarbossamidici |
| CA2388593A1 (en) | 1999-11-12 | 2001-05-17 | Neurogen Corporation | Bicyclic and tricyclic heteroaromatic compounds |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| KR20040027870A (ko) | 2001-07-05 | 2004-04-01 | 시냅틱 파마세틱칼 코포레이션 | Ｍｃｈ 선택적인 안타고니스트로서의 치환 아닐린 피페리딘 |
| EP1285914B1 (en) | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| WO2003044017A1 (en) | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| GB0128160D0 (en) | 2001-11-23 | 2002-01-16 | Merck Sharp & Dohme | Novel compounds |
| GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| US7319109B2 (en) | 2002-11-22 | 2008-01-15 | Smith Kline Beecham Corporation | Farnesoid X receptor agonists |
| GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
| US7820705B2 (en) | 2004-05-14 | 2010-10-26 | Irm Llc | Compounds and compositions as PPAR modulators |
| PL1756086T3 (pl) | 2004-06-01 | 2008-11-28 | Hoffmann La Roche | Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5 |
| WO2005123672A2 (en) | 2004-06-14 | 2005-12-29 | Takeda San Diego, Inc. | Kinase inhibitors |
| MX2007003648A (es) | 2004-10-01 | 2007-06-11 | Hoffmann La Roche | Derivados de eter sustituido con hexafluoroisopropanol. |
| US7351724B2 (en) | 2004-10-15 | 2008-04-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| WO2006095822A1 (ja) | 2005-03-11 | 2006-09-14 | Ono Pharmaceutical Co., Ltd. | スルホンアミド化合物およびその医薬 |
| ES2352796T3 (es) | 2005-06-27 | 2011-02-23 | Bristol-Myers Squibb Company | Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas. |
| ATE532668T1 (de) | 2005-07-20 | 2011-11-15 | Prospective Concepts Ag | Pneumatische kissenstrukturen |
| KR100976675B1 (ko) | 2005-09-19 | 2010-08-18 | 에프. 호프만-라 로슈 아게 | Ｇａｂａ ａ 알파5 역작용물질로서의 아이속사졸로 유도체 |
| AU2006301376A1 (en) | 2005-10-11 | 2007-04-19 | F. Hoffmann-La Roche Ag | Isoxazole derivatives |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| AU2006319232B2 (en) * | 2005-11-30 | 2012-09-13 | F. Hoffmann-La Roche Ag | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as H3 modulators |
| ATE526318T1 (de) | 2005-12-19 | 2011-10-15 | Glaxosmithkline Llc | Farnesoid-x-rezeptor-agonisten |
| WO2007071476A1 (en) * | 2005-12-20 | 2007-06-28 | International Business Machines Corporation | Method, system and computer program for distributing software products based on an e-mail service |
| CN101374834B (zh) | 2006-02-03 | 2011-12-14 | 伊莱利利公司 | 用于调节fxr的化合物和方法 |
| JP2007230909A (ja) | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | 置換イソキサゾール誘導体 |
| WO2007137954A1 (en) | 2006-05-31 | 2007-12-06 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| EP2474549A1 (en) | 2007-04-17 | 2012-07-11 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| HUE025545T2 (en) | 2007-12-04 | 2016-03-29 | Hoffmann La Roche | Isoxazole-pyridine derivatives |
| AU2008333320B2 (en) | 2007-12-04 | 2012-12-20 | F. Hoffmann-La Roche Ag | Isoxazolo-pyrazine derivatives |
-
2012
- 2012-10-12 US US13/650,159 patent/US8785435B2/en active Active
- 2012-10-17 JP JP2014536209A patent/JP5918856B2/ja active Active
- 2012-10-17 PL PL12772789T patent/PL2768821T3/pl unknown
- 2012-10-17 DK DK12772789.9T patent/DK2768821T3/en active
- 2012-10-17 AU AU2012318294A patent/AU2012318294B2/en not_active Ceased
- 2012-10-17 ES ES12772789.9T patent/ES2606547T3/es active Active
- 2012-10-17 SG SG11201401591WA patent/SG11201401591WA/en unknown
- 2012-10-17 CA CA2850441A patent/CA2850441A1/en not_active Abandoned
- 2012-10-17 EP EP12772789.9A patent/EP2768821B1/en active Active
- 2012-10-17 WO PCT/EP2012/070522 patent/WO2013057124A1/en not_active Ceased
- 2012-10-17 CN CN201280051089.3A patent/CN103889971B/zh active Active
- 2012-10-17 MX MX2014004678A patent/MX341492B/es active IP Right Grant
- 2012-10-17 BR BR112014009288A patent/BR112014009288A8/pt not_active IP Right Cessation
- 2012-10-17 RU RU2014118968A patent/RU2618524C2/ru not_active IP Right Cessation
- 2012-10-17 AR ARP120103860A patent/AR088359A1/es unknown
- 2012-10-17 SI SI201230792A patent/SI2768821T1/sl unknown
- 2012-10-17 HU HUE12772789A patent/HUE030298T2/en unknown
- 2012-10-17 KR KR1020147013555A patent/KR20140079503A/ko not_active Ceased
-
2014
- 2014-03-13 IL IL231532A patent/IL231532A0/en active IP Right Grant
- 2014-06-04 US US14/295,535 patent/US8975397B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014530832A (ja) | 2014-11-20 |
| EP2768821B1 (en) | 2016-11-16 |
| CN103889971B (zh) | 2016-08-31 |
| MX341492B (es) | 2016-08-23 |
| US20130172329A1 (en) | 2013-07-04 |
| WO2013057124A1 (en) | 2013-04-25 |
| NZ622215A (en) | 2016-06-24 |
| IL231532A0 (en) | 2014-04-30 |
| BR112014009288A8 (pt) | 2020-04-22 |
| HUE030298T2 (en) | 2017-04-28 |
| AU2012318294B2 (en) | 2015-10-01 |
| MX2014004678A (es) | 2014-05-28 |
| SG11201401591WA (en) | 2014-05-29 |
| RU2618524C2 (ru) | 2017-05-04 |
| PL2768821T3 (pl) | 2017-05-31 |
| CA2850441A1 (en) | 2013-04-25 |
| CN103889971A (zh) | 2014-06-25 |
| US20140329806A1 (en) | 2014-11-06 |
| RU2014118968A (ru) | 2015-11-27 |
| DK2768821T3 (en) | 2017-01-23 |
| SI2768821T1 (sl) | 2017-01-31 |
| JP5918856B2 (ja) | 2016-05-18 |
| US8975397B2 (en) | 2015-03-10 |
| EP2768821A1 (en) | 2014-08-27 |
| AU2012318294A1 (en) | 2013-05-09 |
| ES2606547T3 (es) | 2017-03-24 |
| KR20140079503A (ko) | 2014-06-26 |
| HK1193611A1 (zh) | 2014-09-26 |
| US8785435B2 (en) | 2014-07-22 |
| BR112014009288A2 (pt) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX367618B (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
| ECSP109921A (es) | Sulfonamidas como moduladores de trpm8 | |
| GT201300179A (es) | Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos | |
| CO6511283A2 (es) | Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer | |
| ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
| MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| ATE522249T1 (de) | Organische verbindungen | |
| CO6480975A2 (es) | Mimetico de smac | |
| BR112015024907A2 (pt) | n-acil-(3-substituido)-(8-substituido)-5,6-dihidro-[1,2,4]triazol[4,3a]pirazinas como antagonistas receptores seletivos de nk-3, composição farmacêutica, métodos para uso em desordens mediadas por receptores de nk-3 | |
| CO6700831A2 (es) | Derivados de pirazina como bloqueadores de enac | |
| EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
| PH12015500376B1 (en) | Novel bicyclic pyridinones | |
| DOP2009000287A (es) | Oxazolidinonas sustituidas y su uso | |
| UY34912A (es) | Antagonistas del receptor de 5-ht3 | |
| AR088359A1 (es) | FORMAS POLIMORFICAS DEL (1,1-DIOXO-l-4-TIOMORFOLINIL)-{6-[3-(4-FLUOROFENIL)-5-METIL-ISOXAZOL-4-ILMETOXI]-PIRIDIN-3-IL}-METANONA Y SU USO EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS | |
| CL2016000496A1 (es) | Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias. | |
| IN2012DN03846A (es) | ||
| AR084832A1 (es) | Derivado cristalino de oxazina | |
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| DOP2010000317A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
| EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
| MX2015001657A (es) | Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar). | |
| CY1117011T1 (el) | Παραγωγα αζολιου | |
| MX2014005538A (es) | 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1). | |
| CY1119702T1 (el) | Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |